Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Nu-Med Plus (NUMD) EBIAT (2016 - 2025)

Nu-Med Plus' EBIAT history spans 10 years, with the latest figure at -$112341.0 for Q4 2021.

  • On a quarterly basis, EBIAT rose 77.23% to -$112341.0 in Q4 2021 year-over-year; TTM through Dec 2021 was -$830061.0, a 58.68% increase, with the full-year FY2025 number at -$56182.0, up 17.8% from a year prior.
  • EBIAT hit -$112341.0 in Q4 2021 for Nu-Med Plus, up from -$118366.0 in the prior quarter.
  • Over the last five years, EBIAT for NUMD hit a ceiling of $4.0 million in Q1 2017 and a floor of -$908467.0 in Q2 2020.
  • Historically, EBIAT has averaged -$74386.5 across 5 years, with a median of -$191712.5 in 2018.
  • Biggest five-year swings in EBIAT: soared 81.48% in 2017 and later plummeted 268.48% in 2018.
  • Tracing NUMD's EBIAT over 5 years: stood at -$152619.0 in 2017, then plummeted by 123.4% to -$340957.0 in 2018, then surged by 38.45% to -$209870.0 in 2019, then tumbled by 135.09% to -$493374.0 in 2020, then skyrocketed by 77.23% to -$112341.0 in 2021.
  • Business Quant data shows EBIAT for NUMD at -$112341.0 in Q4 2021, -$118366.0 in Q3 2021, and -$242606.0 in Q2 2021.